Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI305 plus chemotherapy vs chemotherapy in EGFR-TKI–failed non-squamous NSCLC
CTR20190968Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Non-small cell lung cancer (NS-NSCLC), sponsored by InnoCare Pharma. Started Jun 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20190968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190968.